Want to see JAZZ full AI Analyst Report?

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

1,902 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JAZZ Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Jazz

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$264.50

▲(30.03% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $264.50 with a high forecast of $307.00 and a low forecast of $229.00. The average price target represents a 30.03% change from the last price of $203.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"108":"$108","158":"$158","208":"$208","258":"$258","308":"$308"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":307,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$307.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":264.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$264.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":229,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$229.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[108,158,208,258,308],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,237.51,242.8553846153846,248.20076923076923,253.54615384615383,258.89153846153846,264.23692307692306,269.58230769230767,274.9276923076923,280.2730769230769,285.61846153846153,290.96384615384613,296.3092307692308,301.6546153846154,{"y":307,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,237.51,239.58615384615385,241.66230769230768,243.73846153846154,245.81461538461537,247.89076923076922,249.96692307692308,252.0430769230769,254.11923076923077,256.1953846153846,258.27153846153846,260.3476923076923,262.42384615384617,{"y":264.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,237.51,236.8553846153846,236.20076923076923,235.54615384615383,234.89153846153846,234.23692307692306,233.5823076923077,232.9276923076923,232.27307692307693,231.61846153846153,230.96384615384616,230.30923076923077,229.6546153846154,{"y":229,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":109.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.64,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$307.00

Average Price Target$264.50

Lowest Price Target$229.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gary Nachman

Canaccord Genuity

$290

Buy

42.56%

Upside

Initiated

07/17/26

Jazz Pharmaceuticals initiated with a Buy at CanaccordJazz Pharmaceuticals initiated with a Buy at Canaccord

Etzer Darout

Barclays

$253→$260

Buy

27.81%

Upside

Reiterated

07/14/26

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Barclays

Mohit Bansal

Wells Fargo

$265→$285

Buy

40.10%

Upside

Assigned

07/14/26

Jazz Pharmaceuticals price target raised to $285 from $265 at Wells FargoJazz Pharmaceuticals price target raised to $285 from $265 at Wells Fargo

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$265→$282

Buy

38.63%

Upside

Reiterated

07/13/26

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

07/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Hoang

Deutsche Bank

$250→$270

Buy

32.73%

Upside

Reiterated

07/09/26

Deutsche Bank Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

Leonid Timashev

RBC Capital

$258

Buy

26.83%

Upside

Reiterated

07/07/26

RBC Capital Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Gregory Renza

Truist Financial

$256→$254

Buy

24.86%

Upside

Reiterated

07/07/26

Jazz Pharmaceuticals price target lowered to $254 from $256 at TruistJazz Pharmaceuticals price target lowered to $254 from $256 at Truist

Ashwani Verma

UBS

$307

Buy

50.92%

Upside

Reiterated

07/01/26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), BeOne Medicines (NASDAQ: ONC) and Zevra Therapeutics (NASDAQ: ZVRA)

Ami Fadia

Needham

$255

Buy

25.36%

Upside

Reiterated

06/29/26

Analysts' Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)

David Amsellem

Piper Sandler

$301

Buy

47.97%

Upside

Reiterated

06/16/26

Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Joseph Thome

TD Cowen

$275

Buy

35.19%

Upside

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Edwards Lifesciences (NYSE: EW)

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

06/02/26

Jessica Fye Reaffirms Buy on Jazz Pharmaceuticals, Citing Blockbuster Potential for Zanidatamab in First-Line HER2-Positive Gastric and Esophageal Cancers

Annabel Samimy

Stifel Nicolaus

$230

Buy

13.07%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), SOPHiA GENETICS (NASDAQ: SOPH) and Solventum Corporation (NYSE: SOLV)

Tiago Fauth

Raymond James

$239

Buy

17.49%

Upside

Reiterated

05/06/26

Raymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gary Nachman

Canaccord Genuity

$290

Buy

42.56%

Upside

Initiated

07/17/26

Jazz Pharmaceuticals initiated with a Buy at CanaccordJazz Pharmaceuticals initiated with a Buy at Canaccord

Etzer Darout

Barclays

$253→$260

Buy

27.81%

Upside

Reiterated

07/14/26

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Barclays

Mohit Bansal

Wells Fargo

$265→$285

Buy

40.10%

Upside

Assigned

07/14/26

Jazz Pharmaceuticals price target raised to $285 from $265 at Wells FargoJazz Pharmaceuticals price target raised to $285 from $265 at Wells Fargo

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$265→$282

Buy

38.63%

Upside

Reiterated

07/13/26

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

07/10/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Hoang

Deutsche Bank

$250→$270

Buy

32.73%

Upside

Reiterated

07/09/26

Deutsche Bank Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

Leonid Timashev

RBC Capital

$258

Buy

26.83%

Upside

Reiterated

07/07/26

RBC Capital Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Gregory Renza

Truist Financial

$256→$254

Buy

24.86%

Upside

Reiterated

07/07/26

Jazz Pharmaceuticals price target lowered to $254 from $256 at TruistJazz Pharmaceuticals price target lowered to $254 from $256 at Truist

Ashwani Verma

UBS

$307

Buy

50.92%

Upside

Reiterated

07/01/26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), BeOne Medicines (NASDAQ: ONC) and Zevra Therapeutics (NASDAQ: ZVRA)

Ami Fadia

Needham

$255

Buy

25.36%

Upside

Reiterated

06/29/26

Analysts' Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)

David Amsellem

Piper Sandler

$301

Buy

47.97%

Upside

Reiterated

06/16/26

Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Joseph Thome

TD Cowen

$275

Buy

35.19%

Upside

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Edwards Lifesciences (NYSE: EW)

Jessica Fye

J.P. Morgan

―

Buy

―

Reiterated

06/02/26

Jessica Fye Reaffirms Buy on Jazz Pharmaceuticals, Citing Blockbuster Potential for Zanidatamab in First-Line HER2-Positive Gastric and Esophageal Cancers

Annabel Samimy

Stifel Nicolaus

$230

Buy

13.07%

Upside

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), SOPHiA GENETICS (NASDAQ: SOPH) and Solventum Corporation (NYSE: SOLV)

Tiago Fauth

Raymond James

$239

Buy

17.49%

Upside

Reiterated

05/06/26

Raymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ENOVEnovis

GKOSGlaukos

IMUXImmunic

AVTXAvalo Therapeutics

TARAProtara Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months

Joseph ThomeTD Cowen

Success Rate

13/20 ratings generated profit

Average Return

+6.33%

Copying Joseph Thome's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +6.33% per trade.

1 Year

Joseph ThomeTD Cowen

Success Rate

19/20 ratings generated profit

Average Return

+40.16%

Copying Joseph Thome's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +40.16% per trade.

2 Years

Joseph ThomeTD Cowen

Success Rate

20/20 ratings generated profit

Average Return

+70.80%

Copying Joseph Thome's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +70.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JAZZ has received 34 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 264.50.

Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $6.21 with a range of $5.53 to $7.08. The previous quarter’s EPS was $6.34. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.11B with a range of $1.07B to $1.16B. The previous quarter’s sales results were $1.07B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?

Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 264.50.

What is JAZZ’s upside potential, based on the analysts’ average price target?

Jazz Pharmaceuticals has 30.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JAZZ a Buy, Sell or Hold?

Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is Jazz Pharmaceuticals’s price target?

The average price target for Jazz Pharmaceuticals is 264.50. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $307.00 ,the lowest forecast is $229.00. The average price target represents 30.03% Increase from the current price of $203.42.

What do analysts say about Jazz Pharmaceuticals?

Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of JAZZ?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

JAZZ Analyst Ratings

JAZZ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jazz Pharmaceuticals

JAZZ Analyst Recommendation Trends

JAZZ Financial Forecast

JAZZ Earnings Forecast

JAZZ Sales Forecast

JAZZ Stock Forecast FAQ

Detailed List of Analyst Forecasts